Charles River Laboratories International (NYSE:CRL) Reaches New 1-Year Low - Here's What Happened

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $157.69 and last traded at $159.07, with a volume of 100569 shares. The stock had previously closed at $163.79.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on CRL shares. JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating on the stock in a report on Monday, February 3rd. UBS Group reaffirmed a "neutral" rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Morgan Stanley lowered their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. StockNews.com lowered shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. Finally, TD Cowen lifted their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research note on Monday, November 11th. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and a consensus price target of $200.79.

Charles River Laboratories International Trading Down 0.5 %

The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The stock has a fifty day moving average of $177.23 and a 200-day moving average of $191.71. The company has a market cap of $7.83 billion, a PE ratio of 19.17, a PEG ratio of 6.47 and a beta of 1.37.

Institutional Trading of Charles River Laboratories International

Institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP raised its position in Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock valued at $736,819,000 after purchasing an additional 3,738,018 shares in the last quarter. Norges Bank bought a new stake in shares of Charles River Laboratories International in the fourth quarter valued at about $98,886,000. Allspring Global Investments Holdings LLC lifted its stake in Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock worth $346,821,000 after acquiring an additional 509,163 shares during the period. Raymond James Financial Inc. bought a new position in Charles River Laboratories International during the 4th quarter worth about $42,776,000. Finally, Invesco Ltd. increased its position in Charles River Laboratories International by 17.1% during the 4th quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company's stock valued at $190,910,000 after purchasing an additional 151,159 shares during the period. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).